Pilot study on the efficacy and safty of low-dose tocilizumab therapy in elderly RA patients

Pilot study on the efficacy and safty of low-dose tocilizumab therapy in elderly RA patients - Pilot study on low-dose tocilizumab therapy in elderly RA patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008185

Enrollment

Registered

2012-06-25

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: RA patients who are 65 years old or more will be enrolled after informed concent is taken. Candidates should be under the treatment in Kyushu University Beppu Hospital, Beppu, Japan. The patients should fulfill the ACR RA criteria 1987. DAS28-ESR should be more than 3.2 for past 3 months even after being treated with DMARDs or anti-TNF therapy.

Exclusion criteria

Exclusion criteria: Pateints whose RA stage is Steinbroker IV. Patients who have ever been treated with tocilizumab. Patients who are given 10mg or more PSL daily within 4 weeks.

Design outcomes

Primary

Measure	Time frame
number of patients who effectively completed the low-dose tocilizumab (4mg/kgBW) therapy until 24 weeks after initiation	—

Secondary

Measure	Time frame
Change of DAS28-ESR, CDAI, SDAI, CRP and ESR before and 24 weeks after tocilizumab therapy adverse effects	—

Countries

Japan

Outcome results